Successful use of subcutaneous recombinant human erythropoietin before cholecystectomy in an anemic patient with religious objections to transfusion therapy.
Use of recombinant human erythropoietin has been advocated for therapy in anemic patients with end-stage renal disease and to enhance the harvesting of autologous red blood cells from healthy patients scheduled for elective orthopedic surgery. The authors report the case of a diabetic patient with moderate chronic renal failure and cholelithiasis but whose religious beliefs forbade the use of transfusion therapy. She underwent successful cholecystectomy only after treatment with recombinant human erythropoietin.
Fletcher
J L
JL
Department of Family Medicine, Medical College of Georgia, Augusta.
Perez
J C
JC
Jones
D H
DH
D000740:Anemia / Q000517:prevention & control*; D001803:Blood Transfusion; D002763:Cholecystectomy; D002764:Cholecystitis / Q000601:surgery; D002769:Cholelithiasis / Q000601:surgery; D002835:Christianity; D004921:Erythropoietin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008875:Middle Aged; D011994:Recombinant Proteins; D012068:Religion and Medicine
D011994:Recombinant Proteins; D004921:Erythropoietin